To investigate how concurrent MYC and mitochondrial inhibition shapes tumor metabolism, we performed untargeted metabolomic profiling of MycCaP tumors harvested after 7 days of treatment with vehicle, MYCi975, metformin, or their combination. Here, MYC is linked to neoplasm.